Lytenava (bevacizumab-vikg)

Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Indication
Published: 2026-09-28T12:24:10-04:00

Neovascular age-related macular degeneration

Manufacturer: Outlook Therapeutics
Regulatory submission: BLA approved July 2026
Launch: Anticipated before the end of 2026
Last updated: September 28, 2026

Section

Product information and disease description Product description Product information

Indication

1 evidence topic · 1 source

Indication

“LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).” (opens the prescribing information at this quote)